Method for assay on the effect of vascularization inhibitor
The present invention provides a method of predicting the antitumor effect of an angiogenesis inhibitor. It is possible to predict the antitumor effect of an angiogenesis inhibitor by evaluating the EOF dependency of a tumor cell for proliferation and/or survival and using the EGF dependency as an indicator. Since the antitumor effect of an angiogenesis inhibitor correlates with the EGF dependency of a tumor cell for proliferation and/or survival, the angiogenesis inhibitors is capable of producing excellent antitumor effect when combined with a substance having EGF inhibitory activity.
1. A method for treating an EGF-dependent cancer, which method comprises administering, to a patient in need thereof, an effective amount of a VEGF receptor kinase inhibitor in combination with an effective amount of a substance having EGF inhibitory activity, wherein the VEGF receptor kinase inhibitor is a compound selected from the group consisting of:
4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide,
4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide,
N6-methoxy-4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide,
4-(3-chloro-4-(methylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide,
N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide and
pharmacologically acceptable salts and solvates thereof; and
wherein the substance having EGF inhibitor activity is at least one compound selected from the group consisting of:
4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-(4-morpholino) propoxy-quinazoline),
4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-quinazoline,
N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]-amino]methyl]furan-2-yl]quinazoline-4-amine,
N-[4-[N-(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-quinazoline-6-yl]acrylamide,
(2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide,
[6-[4-[(4-ethylpiperazine-1-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-4-yl]-((R)-1-phenylethyl)amine,
(E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and
pharmacologically acceptable salts and solvates thereof.
2. The method according to claim 1 , wherein the VEGF receptor kinase inhibitor is 4-(3-chloro-4-(cyclorpopylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, a pharmacologically acceptable salt thereof, or a solvate of said compound or salt.
3. The method according to claim 1 , wherein the VEGF receptor kinase inhibitor is a methanesulfphonic acid salt of 4-(3-chloro-4-(cyclorpopylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.
4. The method according to claim 1 , wherein the substance having EGF inhibitor activity is 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-quinazoline, a pharmacologically acceptable salt thereof, or a solvate of said compound or salt.